PharmaGap Inc. has developed novel drugs targeting Protein Kinase C (PKC). The Company’s pre-clinical lead drug candidate (GAP-107B8) is being developed to treat cancer. Aberrant over-expression of PKC is associated with many types of cancer and is a validated therapeutic target. 

GAP-107B8 was developed employing proprietary computer models PharmaGap researchers have developed for select PKC isoforms. PharmaGap’s computer modeling abilities are a core competency and form the basis for the Company’s intellectual property and pipeline of drug compounds targeting PKC for the treatment of cancer and other diseases.

PharmaGap is pursuing a strategy to partner its lead drug candidates at the pre-clinical or early clinical trial stage.  The Company recognizes that its strengths rest in drug design and “proof of principle” validation and that larger pharmaceutical/biotech partners have the resources necessary to move the Company’s compounds into human clinical use.

PharmaGap is a spin-out from Canada’s premier biological research organization, the National Research Council of Canada. Offices and labs are located in Ottawa, Ontario, Canada.

	PharmaGap attended the American Association for Cancer Research (AACR) 101st annual meeting in Washington DC in April 2010
Please click here to view a photo of PharmaGap personnel with collaborators from the Ottawa Hospital Research Institute presenting their data at AACR showing the potent effect of PharmaGap’s novel drug compound (GAP-107B8) in ovarian cancer. Click here in order to review the data poster presented at AACR by researchers from the Ottawa Hospital Research Institute.